2/2
02:31 pm
idya
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
Low
Report
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
2/2
06:26 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
2/2
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
2/2
12:20 am
idya
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
1/30
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/24
05:08 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:17 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/11
01:27 pm
idya
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
12:00 pm
idya
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
1/7
10:57 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
1/6
09:02 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $60.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $60.00 price target on by analysts at Truist Financial Corporation.
1/5
06:17 am
idya
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
06:00 am
idya
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
12/14
07:44 pm
idya
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
Medium
Report
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
12/11
06:27 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
12/11
06:00 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
12/10
06:42 am
idya
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers [Yahoo! Finance]
12/10
06:00 am
idya
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
Low
Report
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
12/4
07:20 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
12/1
06:00 am
idya
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Medium
Report
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
11/30
02:17 am
idya
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]
Medium
Report
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]
11/28
06:34 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/28
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)